Carlomagno F - Search Results

1

RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block.

Alfano L, Guida T, Provitera L, Vecchio G, Billaud M, Santoro M, Carlomagno F. Alfano L, et al. Among authors: carlomagno f. J Clin Endocrinol Metab. 2010 Jul;95(7):3552-7. doi: 10.1210/jc.2009-2315. Epub 2010 May 5. J Clin Endocrinol Metab. 2010. PMID: 20444924

2

Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della Porta G, Berger N, et al. Santoro M, et al. Among authors: carlomagno f. J Clin Invest. 1992 May;89(5):1517-22. doi: 10.1172/JCI115743. J Clin Invest. 1992. PMID: 1569189 Free PMC article.

3

RET/PTC activation in human thyroid carcinomas.

Fusco A, Santoro M, Grieco M, Carlomagno F, Dathan N, Fabien N, Berlingieri MT, Li Z, De Franciscis V, Salvatore D, et al. Fusco A, et al. Among authors: carlomagno f. J Endocrinol Invest. 1995 Feb;18(2):127-9. doi: 10.1007/BF03349720. J Endocrinol Invest. 1995. PMID: 7629379 No abstract available.

4

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.

Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, et al. Santoro M, et al. Among authors: carlomagno f. Science. 1995 Jan 20;267(5196):381-3. doi: 10.1126/science.7824936. Science. 1995. PMID: 7824936

5

Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line.

Carlomagno F, Salvatore D, Santoro M, de Franciscis V, Quadro L, Panariello L, Colantuoni V, Fusco A. Carlomagno F, et al. Biochem Biophys Res Commun. 1995 Feb 27;207(3):1022-8. doi: 10.1006/bbrc.1995.1287. Biochem Biophys Res Commun. 1995. PMID: 7864888

6

Frequent RET protooncogene mutations in multiple endocrine neoplasia type 2A.

Quadro L, Panariello L, Salvatore D, Carlomagno F, Del Prete M, Nunziata V, Colantuoni V, Di Giovanni G, Brandi ML, Mannelli M, et al. Quadro L, et al. Among authors: carlomagno f. J Clin Endocrinol Metab. 1994 Aug;79(2):590-4. doi: 10.1210/jcem.79.2.7913936. J Clin Endocrinol Metab. 1994. PMID: 7913936

7

Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene: analysis of its expression in normal and transformed thyroid cells.

Santoro M, Battaglia C, Zhang L, Carlomagno F, Martelli ML, Salvatore D, Fusco A. Santoro M, et al. Among authors: carlomagno f. Exp Cell Res. 1994 Aug;213(2):398-403. doi: 10.1006/excr.1994.1215. Exp Cell Res. 1994. PMID: 8050496

8

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.

Santoro M, Sabino N, Ishizaka Y, Ushijima T, Carlomagno F, Cerrato A, Grieco M, Battaglia C, Martelli ML, Paulin C, et al. Santoro M, et al. Among authors: carlomagno f. Br J Cancer. 1993 Sep;68(3):460-4. doi: 10.1038/bjc.1993.370. Br J Cancer. 1993. PMID: 8353035 Free PMC article.

9

Molecular heterogeneity of RET loss of function in Hirschsprung's disease.

Carlomagno F, De Vita G, Berlingieri MT, de Franciscis V, Melillo RM, Colantuoni V, Kraus MH, Di Fiore PP, Fusco A, Santoro M. Carlomagno F, et al. EMBO J. 1996 Jun 3;15(11):2717-25. EMBO J. 1996. PMID: 8654369 Free PMC article.

10

The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.

Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Franciscis V, Billaud M, Fusco A, Santoro M. Carlomagno F, et al. Cancer Res. 1997 Feb 1;57(3):391-5. Cancer Res. 1997. PMID: 9012462

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

130 results

Search Page